Oncobiologics (OTLK) Competitors $1.93 -0.03 (-1.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.95 +0.02 (+1.04%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. ACB, MNPR, IMMP, INZY, CRDF, EDIT, REPL, AVTE, BTMD, and FENCShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Aurora Cannabis (ACB), Monopar Therapeutics (MNPR), Prima BioMed (IMMP), Inozyme Pharma (INZY), Cardiff Oncology (CRDF), Editas Medicine (EDIT), Replimune Group (REPL), Aerovate Therapeutics (AVTE), biote (BTMD), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Aurora Cannabis Monopar Therapeutics Prima BioMed Inozyme Pharma Cardiff Oncology Editas Medicine Replimune Group Aerovate Therapeutics biote Adherex Technologies Aurora Cannabis (NASDAQ:ACB) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Which has more volatility and risk, ACB or OTLK? Aurora Cannabis has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Do analysts rate ACB or OTLK? Oncobiologics has a consensus price target of $9.60, suggesting a potential upside of 397.41%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is ACB or OTLK more profitable? Aurora Cannabis has a net margin of 1.32% compared to Oncobiologics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Oncobiologics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis1.32% 0.13% 0.10% Oncobiologics N/A N/A -271.12% Do institutionals and insiders have more ownership in ACB or OTLK? 47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 4.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ACB or OTLK? Aurora Cannabis has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.02$1.63M$0.1140.73OncobiologicsN/AN/A-$75.37M-$0.91-2.12 Does the media prefer ACB or OTLK? In the previous week, Aurora Cannabis had 2 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.84 beat Aurora Cannabis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Overall Sentiment Aurora Cannabis Neutral Oncobiologics Positive SummaryAurora Cannabis beats Oncobiologics on 12 of the 16 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.79M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.1217.7428.8623.83Price / SalesN/A178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book-0.628.508.275.54Net Income-$75.37M-$55.06M$3.25B$259.28M7 Day Performance-5.39%-3.99%-3.73%-4.68%1 Month Performance12.87%9.58%4.29%4.36%1 Year Performance-73.67%6.70%25.87%17.89% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.4934 of 5 stars$1.93-1.5%$9.60+397.4%-73.9%$65.79MN/A-2.1220News CoverageACBAurora Cannabis0.3706 of 5 stars$4.78-1.2%N/A-26.0%$268.86M$343.29M43.451,130Upcoming EarningsMNPRMonopar Therapeutics1.9638 of 5 stars$43.40-3.5%$60.00+38.2%+1,074.0%$265.61MN/A-12.4710Upcoming EarningsIMMPPrima BioMed1.4577 of 5 stars$1.80+4.7%$7.00+288.9%-17.1%$262.87MN/A0.002,021News CoveragePositive NewsINZYInozyme Pharma2.1153 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750News CoverageUpcoming EarningsCRDFCardiff Oncology1.797 of 5 stars$3.73-6.0%$11.70+213.7%+14.3%$248.16M$680K-4.0520Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpHigh Trading VolumeEDITEditas Medicine3.968 of 5 stars$2.96-6.0%$4.70+58.8%-52.5%$247.79M$35.84M-0.97230News CoverageUpcoming EarningsREPLReplimune Group3.8866 of 5 stars$3.17+0.6%$7.67+141.9%-25.6%$244.37MN/A-1.03210Trending NewsAnalyst UpgradeOptions VolumeGap DownHigh Trading VolumeAVTEAerovate TherapeuticsN/A$8.28-0.6%N/A-88.5%$240.00MN/A-2.7720High Trading VolumeBTMDbiote2.9814 of 5 stars$4.37+1.2%$8.00+83.1%-48.0%$239.08M$197.19M7.16194News CoverageUpcoming EarningsFENCAdherex Technologies1.8179 of 5 stars$8.66+0.3%$13.00+50.1%+25.0%$239.02M$30.91M-16.9810 Related Companies and Tools Related Companies Aurora Cannabis Competitors Monopar Therapeutics Competitors Prima BioMed Competitors Inozyme Pharma Competitors Cardiff Oncology Competitors Editas Medicine Competitors Replimune Group Competitors Aerovate Therapeutics Competitors biote Competitors Adherex Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
